Print Page  Close Window

Investor Center Home
Corporate Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

More >>

BLCM (Common Stock)
(US Dollar)
Price$12.26
Change Stock is Down 0.34
(%)Volume (2.70%)207,001
ExchangeNASDAQ
Data as of 05/22/17 3:06 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
05/18/17Bellicum Announces Clinical Presentations at the 22nd Congress of the European Hematology AssociationPrinter Friendly Version
05/15/17Bellicum Pharmaceuticals Announces Management ChangesPrinter Friendly Version
05/08/17Bellicum Pharmaceuticals Reports First Quarter 2017 Financial ResultsPrinter Friendly Version
04/26/17Bellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care ConferencePrinter Friendly Version
More >>
Upcoming Events
06/14/17 10:00 a.m. CT
Bellicum Pharmaceuticals Inc Annual Shareholder Meeting For holders as of: April 17, 2017
Location: Bellicum Pharmaceuticals, Inc.
2130 West Holcombe Blvd., Suite 800
Houston, TX 77030
06/23/17
Bellicum Pharmaceuticals Inc at European Hematology Association Presentation Details

Oral Presentation - Presidential Symposium: “BPX-501 Donor T-Cell Infusion (with Inducible Caspase 9 Suicide Gene) Facilitates HLA Haploidentical Stem Cell Transplant in Children with both Hematological Malignancies and Non-Malignant Conditions”
Session Title: Presidential Symposium
Date: Friday, June 23
Session Time: 3:45 – 4:00 PM CEST
Location Hall A
Abstract Code: S146

Oral Presentation: “Impact of Post-Transplant Infusion of Donor T-Cells Genetically Modified with Inducible Caspase 9 Suicide Gene (BPX-501 Cells) on Children with Leukemia Given Alpha-Beta T-Cell Depleted Haplo-HSCT”
Session Title: Stem cell transplantation – Clinical 1
Session Name: 732.Clinical Allogeneic Transplantation: Results: Predicting Outcome
Date: Saturday, June 24
Session Time: 5:00 – 5:15 PM CEST
Location: Room N103
Abstract Code: S495

Poster Presentation: “The Use of BPX-501 Donor T-Cell Infusion (with Inducible Caspase 9 Suicide Gene) Together with HLA-Haploidentical Stem Cell Transplant to Treat Children with Hemoglobinopathies and Erythroid Disorders”
Session Title: Stem cell transplantation – Clinical 1
Date: Friday, June 23
Time: 5:15 – 6:45 PM CEST
Session Time: Poster Area (Hall 7)
Presentation Time: 8:45 AM PST

Past Events
05/10/17
through
05/12/17
American Society of Gene & Cell Therapy (ASGCT) 20th Annual Meeting

Poster Presentation: “A dual-switch platform to orthogonally control CAR-T cell efficacy and safety with two non-immunosuppressive chemical inducers of protein dimerization”
Date/Time:Wednesday, May 10, 2017 from 5:30 PM – 7:30 PM EDT

Oral Abstract Presentation: “Dual-Switch CAR-T Cells: Dual Molecular Switches to Control Activation and Elimination of CAR-T Cells to Target CD123+ Cancer"”
Session Name: 345 “Preclinical Optimization of Immunotherapies”
Date/Time: Friday, May 12, 2017 5:00 PM – 5:15 PM EDT

Location: Washington, DC
05/03/17 2:10 p.m. ET
Bellicum Pharmaceuticals Inc at Deutsche Bank 42nd Annual Health Care Conference
Click here for webcast
More >>
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources